A Multicenter, Open-label, Phase I Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity of YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors
Latest Information Update: 08 Jan 2025
At a glance
Most Recent Events
- 06 Jan 2025 Status changed from recruiting to completed.
- 27 May 2022 Planned End Date changed from 16 Jan 2025 to 21 Feb 2025.
- 27 May 2022 Planned primary completion date changed from 16 Jan 2024 to 21 Feb 2024.